{"commentary":{"count":15,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":10,"podcast":3,"youtube":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04698213\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"TIDE-A","nct_id":"NCT04698213","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=tide-a-nct04698213. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"TIDE-A","arms":[{"description":"All patients enrolled in the trail will receive axitinib at 5 mg BID plus avelumab at 10 mg/Kg every two weeks.\n\nTreatment will be continued until progression of disease during the first 36 weeks of therapy. At week 36, patients achieving a tumor decrease ≥ 30% will discontinue axitinib and continue avelumab until progression of disease defined as ≥ 20% increase compared to the tumor burden measured at week 36. At disease progression, axitinib will be restarted at the same dosage used before discontinuation for at least 24 weeks if progression did not occur before. Patients who achieved again tumor decrease of ≥ 30% after 24 weeks of therapy rechallenge with axitinib and avelumab may discontinue axitinib and maintain avelumab until progression of disease in an intermittent manner.","label":"intermittent axitinib plus Avelumab","type":"EXPERIMENTAL"}],"collaborators":["Clinical Research Technology S.r.l."],"completion_date":{"date":"2024-10","type":"ESTIMATED"},"conditions":["Renal Carcinoma Metastatic"],"enrollment":{"count":75,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Axitinib Oral Tablet","type":"DRUG"},{"name":"Avelumab","type":"DRUG"}],"last_update":"2021-01-06","lead_sponsor":"Consorzio Oncotech","official_title":"Phase II Study of Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma (Tide-A Study)","overall_status":"UNKNOWN","phases":["PHASE2"],"primary_completion_date":{"date":"2023-09","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall response rate (ORR)","timeFrame":"From the date of the first study drugs administration until week 44"}],"references":[],"start_date":{"date":"2020-10-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma","url":"https://clinicaltrials.gov/study/NCT04698213"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/tide-a-nct04698213"}